August 1, 2024

Uncategorized

New Releases from NCBI BookshelfElranatamab (Elrexfio): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].​Elranatamab (Elrexfio): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].

CADTH recommends that Elrexfio should be reimbursed by public drug plans for the treatment of adult patients with relapsed or

Uncategorized

New Releases from NCBI BookshelfBimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with active psoriatic arthritis. Bimekizumab can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (e.g., methotrexate) [Internet].​Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with active psoriatic arthritis. Bimekizumab can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (e.g., methotrexate) [Internet].

CADTH recommends that Bimzelx be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain

Scroll to Top